The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Arcus Biosciences Inc. | COM | 03969F109 | 968,825,351 | 31,424,760 | SH | SOLE | 31,424,760 | 0 | 0 | ||
| Assembly Biosciences Inc. | COM NEW | 045396207 | 136,770,406 | 4,977,089 | SH | SOLE | 4,977,089 | 0 | 0 | ||
| Lakefront Biotherapeutics | SPON ADR | 36315X101 | 500,157,715 | 16,707,477 | SH | SOLE | 16,707,477 | 0 | 0 | ||
| Kyverna Therapeutics Inc. | COM | 501976104 | 36,763,720 | 4,126,119 | SH | SOLE | 4,126,119 | 0 | 0 | ||
| Xilio Therapeutics Inc. | COM | 98422T100 | 6,230,727 | 650,389 | SH | SOLE | 650,389 | 0 | 0 | ||